Zimlovisertib

N/A

Report date: 2025/08/20 10:31:52
NME

Base Information

Drug NameZimlovisertib
Drug Alias NamePF-06650833PF-6650833
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, RheumatoidHidradenitis Suppurativa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYale UniversityPfizer Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, RheumatoidHidradenitis Suppurativa

Other Information

ATC CodeN/A
Related LinksN/A